INmune Bio and Quantum Computing partner to apply quantum optimization and AI to advance Alzheimer’s drug research and explore new applications for XPro
INmune Bio (NASDAQ: INMB) and Quantum Computing Inc. (NASDAQ: QUBT) will use QCi's Dirac-3S quantum optimization machine alongside AI and conventional analytics to identify new potential applications for XPro, INmune Bio's investigational Alzheimer's treatment.
Via TNW | Press-release
Boca Raton, Florida, October 14th, 2026, Financewire
Collaboration combines INmune Bio’s clinical research with QCi’s Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro. Initial engagement marks QCi’s first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development.
INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications…
Courtesy
This story was originally published by TNW | Press-release. All rights belong to the original publisher.
Read the original on thenextweb.com ↗